6op9
From Proteopedia
(Difference between revisions)
m (Protected "6op9" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==HER3 pseudokinase domain bound to bosutinib== | |
| - | + | <StructureSection load='6op9' size='340' side='right'caption='[[6op9]], [[Resolution|resolution]] 2.50Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6op9]] is a 1 chain structure. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=4otw 4otw]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OP9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6OP9 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DB8:4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYLPIPERAZIN-1-YL)PROPOXY]QUINOLINE-3-CARBONITRILE'>DB8</scene></td></tr> | |
| - | [[Category: | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6op9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6op9 OCA], [http://pdbe.org/6op9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6op9 RCSB], [http://www.ebi.ac.uk/pdbsum/6op9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6op9 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:[http://omim.org/entry/607598 607598]]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.<ref>PMID:17701904</ref> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Binds and is activated by neuregulins and NTAK.<ref>PMID:15358134</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Receptor protein-tyrosine kinase]] | ||
| + | [[Category: Agnew, C]] | ||
| + | [[Category: Jura, N]] | ||
[[Category: Littlefield, P]] | [[Category: Littlefield, P]] | ||
| - | [[Category: | + | [[Category: Bosutinib]] |
| - | [[Category: | + | [[Category: Membrane]] |
| + | [[Category: Pseudokinase]] | ||
| + | [[Category: Receptor tyrosine kinase]] | ||
| + | [[Category: Signaling protein]] | ||
| + | [[Category: Transferase-transferase inhibitor complex]] | ||
Revision as of 05:44, 21 August 2019
HER3 pseudokinase domain bound to bosutinib
| |||||||||||
